Lausanne-based medical data specialists Sophia Genetics has raised US$110m in an oversubscribed round of Series F funding.
The round was led by aMoon, a leading health-tech & life sciences venture fund based in Israel, and Hitachi Ventures, a venture arm of Japanese Hitachi Group. The company also received the trust of prime financial institutions Credit Suisse and the Pictet group. Existing investors Swisscom Ventures, Endeavour Vision, Generation Investment Management, Alychlo, and Eurazeo Growth participated in the round, as well as newcomers ACE & Company and Famille C Invest.
“Sophia has established an impressive track record of disrupting healthcare and enabling a decentralised approach. This new funding round will further strengthen Sophia’s already unique offering, performance, and life-changing impact on patients and targeted therapies,” said chairman Troy Cox.
Sophia Genetics supports healthcare professionals by translating multiple sources of complex medical data into valuable clinical insights. The Sophia platform is used by more than 1,000 healthcare institutions and has analysed 600,000 genomic profiles; up to 17,000 new profiles a month. Through continual learning and network effects, experts worldwide are empowered to act with confidence for better patient management.
The new funding round will boost the company’s penetration in both the US and Asian markets. Proceeds will also be dedicated to increasing the platform multimodal capabilities and its adoption by healthcare institutions worldwide.